The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...

Neurologists hope this tongue-in-cheek study will spark serious conversations about AI's limitations and the benefits of a ...

A team of researchers at Heriot-Watt University have said they have shown 'extremely encouraging' results in their first ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative, patient-focused treatments, today responded to recent market rumors and inquiries from ...